TMCnet News
Prevail Therapeutics to Participate in Fireside Chat at Chardan 4th Annual Genetic Medicines Manufacturing SummitCEO, CTO to Discuss Company’s Manufacturing and CMC Strategy and Overall Industry Trends NEW YORK, May 21, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer of Prevail, and Yong Dai, Ph.., Chief Technology Officer of Prevail will participate in a virtual fireside chat at the Chardan 4th Annual Genetic Medicines Manufacturing Summit on Tuesday, May 26, 2020. About Prevail Therapeutics Prevail was founded by Dr. Asa Abeliovich in 2017, through a collaborative effort with The Silverstein Foundation for Parkinson’s with GBA and OrbiMed, and is headquartered in New York, NY. Media Contact: Investor Contact: |